In 2018, Gilead and the Mauritius government signed a Memorandum of Understanding to support the elimination of hepatitis C (HCV) through knowledge sharing, disease management, access to innovative drugs, and education of healthcare professionals. Prior to 2018, there was no screening and care pathway for people at risk of or living with HCV in Mauritius. In addition to the donation of treatment, Gilead has collaboratively developed a new initiative to support the identification, screening and treatment of people living with HCV – improving hepatology services throughout the country. Gilead’s product donation acted as a catalyst for broad system investment, including advancements in technology, laboratory investments, improving public health understanding, and the training of nurses and doctors.

As of 2018, out of the estimated 9,000 people living with HCV in Mauritius, ~5,000 are yet to receive a positive diagnosis. The Mauritius government estimates these patients can be diagnosed and treated within 3 years if we can continue at current rates.